^
    19d
    CRIUS-1: First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer (clinicaltrials.gov)
    P1/2, N=42, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    1m
    Efficacy of VTP-300 in Chronic Hepatitis B Infection (clinicaltrials.gov)
    P2, N=121, Completed, Barinthus Biotherapeutics | Active, not recruiting --> Completed | Trial completion date: Oct 2026 --> Jan 2026
    Trial completion • Trial completion date
    |
    Opdivo (nivolumab)
    2ms
    CRIUS-1: First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer (clinicaltrials.gov)
    P1/2, N=42, Not yet recruiting, AstraZeneca
    New P1/2 trial • First-in-human
    2ms
    ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) (clinicaltrials.gov)
    P1, N=120, Active, not recruiting, USWM CT, LLC | Trial primary completion date: Apr 2026 --> Dec 2026
    Trial primary completion date
    |
    MAGEA4 (Melanoma antigen family A, 4)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • uzatresgene autoleucel (ADP-A2M4CD8)
    3ms
    TITAN: A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. (clinicaltrials.gov)
    P1, N=72, Recruiting, AstraZeneca | N=32 --> 72
    Enrollment change
    3ms
    An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=78, Recruiting, Yonsei University
    New P2 trial
    |
    axitinib • SLC-3010
    4ms
    ABX-001-01: A study to test a new immunotherapy, ABX-001, alone and in combination with the marketed drug, pembrolizumab, for the treatment of tumors previously treated with other therapies. (2024-512403-39-01)
    P1, N=27, Recruiting, Abalos Therapeutics GmbH
    New P1 trial
    |
    Keytruda (pembrolizumab)
    4ms
    ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) (clinicaltrials.gov)
    P1, N=120, Active, not recruiting, USWM CT, LLC | Trial primary completion date: Dec 2025 --> Apr 2026
    Trial primary completion date
    |
    MAGEA4 (Melanoma antigen family A, 4)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • uzatresgene autoleucel (ADP-A2M4CD8)
    6ms
    TITAN: A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. (clinicaltrials.gov)
    P1, N=72, Recruiting, AstraZeneca | N=54 --> 72
    Enrollment change
    6ms
    Phase 1 study evaluating the safety, preliminary efficacy, and pharmacodynamics of recombinant interleukin-15 in combination with nivolumab and ipilimumab in patients with refractory cancers. (PubMed, J Immunother Cancer)
    The combination of rhIL-15 with nivolumab and ipilimumab was safe and induced changes in immune cell populations in some patients. However, preliminary signs of efficacy were limited. Pharmacodynamic findings may support further clinical development of this combination with alternative dosing regimens or combinations of rhIL-15 with other therapeutic modalities.
    P1 data • PK/PD data • Journal
    |
    PD-1 (Programmed cell death 1) • IL15 (Interleukin 15)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • rhIL-15
    6ms
    Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations (clinicaltrials.gov)
    P1, N=24, Recruiting, Fred Hutchinson Cancer Center | Suspended --> Recruiting | Trial completion date: Feb 2026 --> Jan 2028 | Trial primary completion date: Feb 2026 --> Jan 2028
    Enrollment open • Trial completion date • Trial primary completion date • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    KRAS mutation • TMB-H • BRAF mutation • HER-2 amplification • ROS1 fusion • KRAS G12 • NTRK fusion
    |
    cyclophosphamide • bendamustine • fludarabine IV
    7ms
    A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies (clinicaltrials.gov)
    P1, N=27, Recruiting, Abalos Therapeutics GmbH
    New P1 trial • Checkpoint inhibition
    |
    Keytruda (pembrolizumab)